UNSPSC 51172140: Mofloverine

This classification denotes an antispasmotic agent with the molecular formula C16H23NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L1G37N4EBS, chemically known as 2,4,6-trimethoxybenzoic acid 2-morpholinoethyl ester but generally known as mofloverine, which bears US NIH Compound Identifier 172304. European Medicines Agency schedules Mofloverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09036MIG.

UNSPSC 51172140 Mofloverine, a Commodity code, describes pharmaceutical products that state and local governments procure for correction, health, and public-assistance programs. The recent activity shows substantial diversity in how this code is being applied: one solicitation targets offender drug-testing services bundled with specimen collection and lab analysis; another pursues direct-to-manufacturer pharmacy initiatives to bypass traditional benefit managers and wholesalers; and a third establishes cooperative purchasing contracts for generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers to multiple state and local facilities. The work spans clinical specimen handling with regulatory certification (SAMHSA, Texas DPS, or CAP), laboratory screening and confirmation testing using immunoassay and mass spectrometry methods, direct contracting with pharmaceutical manufacturers on net-pricing models, and large-scale generic-drug supply agreements requiring cGMP and Drug Supply Chain Security Act compliance. Issuing bodies include county supervision and corrections departments, state health and human services commissions, and multistate cooperative purchasing alliances on behalf of participating state agencies and local government entities.

Recent activity is concentrated in Texas and the Upper Midwest. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026, estimated contract value $600,000 for two years with three optional one-year renewals), seeking an estimated 25,031 annual tests across five-panel and six-panel screening with LC/MS/MS or GC/MS confirmation and alternative testing methodologies. The Texas Health and Human Services Commission issued Request for Information HHS0017013 in March 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with awards effective July 1, 2026 and participation extending to Oregon.